Therapeutic potential of the TWEAK/FN14 pathway in intractable gastrointestinal cancer

Experimental and Therapeutic Medicine

Volumn 2, Issue 1, 2011, Pages 103-108

  Yoriki, Ryo ^a   Akashi, Satoru ^a   Sho, Masayuki ^a   Nomi, Takeo ^a   Yamato, Ichiro ^a   Hotta, Hotta ^a   Takayama, Tomoyoshi ^a   Matsumoto, Sohei ^a   Wakatsuki, Kohei ^a   Migita, KazuhiroMigita ^a   Yagita, Hideo ^b   Nakajima, Yoshiyuki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal cancer; Fibroblast growth inducible 14; Molecular target therapy; Pancreatic cancer; Tumor necrosis factor like weak inducer of apoptosis

Indexed keywords

CYTOKINE RECEPTOR; FIBROBLAST GROWTH INDUCIBLE 14; FIBROBLAST GROWTH INDUCIBLE 14 ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLORECTAL ADENOCARCINOMA; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG TARGETING; ESOPHAGUS CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION;

EID: 78751635006     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.181     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CACancer JClin 60: 277-300, 2010.
2. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. JClin Oncol 24: 2137-2150, 2006.
3. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
4. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, HessionC, Garcia I and Browning JL: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. JBiol Chem 272: 32401-32410, 1997.
5. Winkles JA: The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7: 411-425, 2008.
6. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA and Fanslow WC: Anovel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15: 837-846, 2001.
7. Kumar M, Makonchuk DY, Li H, Mittal A and Kumar A: TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. JImmunol 182: 2439-2448, 2009.
8. Polek TC, Talpaz M, Darnay BG and Spivak-Kroizman T: TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. JBiol Chem 278: 32317-32323, 2003.
9. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H and Okumura K: Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 299: 488-493, 2002.
10. Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS and Putterman C: TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. JImmunol 179: 7949-7958, 2007.
11. Desplat-Jego S, Creidy R, Varriale S, Allaire N, Luo Y, BernardD, Hahm K, Burkly L and Boucraut J: Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental auto-immune encephalomyelitis. Clin Immunol 117: 15-23, 2005.
12. Perper SJ, Browning B, Burkly LC, et al: TWEAK is a novel arthritogenic mediator. JImmunol 177: 2610-2620, 2006.
13. Kamata K, Kamijo S, Nakajima A, Koyanagi A, KurosawaH, Yagita H and Okumura K: Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. JImmunol 177: 6433-6439, 2006.
14. Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Okano H, Sugimoto K, MurataK and Nakano T: Functional expression of TWEAK in human colonic adenocarcinoma cells. Int JOncol 26: 87-93, 2005.
15. Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Okano H, Sugimoto K, MurataK and Nakano T: Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun 318: 726-733, 2004.
16. Tran NL, McDonough WS, Savitch BA, et al: Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 66: 9535-9542, 2006.
17. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB and vonHoff DD: Identification of differentially expressed genes in pancreatic cancer cells using cDNAmicroarray. Cancer Res 62: 2890-2896, 2002.
18. Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, TestaJR, Peifley KA and Winkles JA: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am JPathol 156: 1253-1261, 2000.
19. Culp PA, Choi D, Zhang Y, et al: Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 16: 497-508, 2010.
20. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA and Berens ME: The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible14 (Fn14) signaling system regulates glioma cell survival via NF kappa B pathway activation and BCL-XL/BCL-W expression. JBiol Chem 280: 3483-3492, 2005.
21. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN and Winkles JA: Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 64: 8968-8972, 2004.
22. Winkles JA, Tran NL and Berens ME: TWEAK and Fn14: new molecular targets for cancer therapy? Cancer Lett 235: 11-17, 2006.
23. Polavarapu R, Gongora MC, Winkles JA and Yepes M: Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation. JNeurosci 25: 10094-10100, 2005.
24. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, WangMZ, Maurer MH, Rossner M, Schneider A and Schwaninger M: Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. JNeurosci 24: 8237-8244, 2004.
25. Nakayama M, Harada N, Okumura K and Yagita H: Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 306: 819-825, 2003.
26. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K and Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. JImmunol 170: 341-348, 2003.
27. Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, Hwang K and Young Lee S: TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem Biophys Res Commun 305: 789-796, 2003.
28. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, NelsonMA, Montgomery EA and Sampliner RE: Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int JCancer 121: 2132-2139, 2007.
29. Wang D, Fung JN, Tuo Y, Hu L and Chen C: TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway. Cancer Lett 294: 91-100, 2010.
30. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, Browning B, Michaelson JS, Baetscher M, Wang B, Bissell DM and Burkly LC: TWEAK induces liver progenitor cell proliferation. JClin Invest 115: 2330-2340, 2005.
31. Tanabe K, Bonilla I, Winkles JA and Strittmatter SM: Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. JNeurosci 23: 9675-9686, 2003.
32. Girgenrath M, Weng S, Kostek CA, et al: TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EmboJ25: 5826-5839, 2006.
33. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. JClin Oncol 25: 1960-1966, 2007.